Amgen starts two critical late-stage trials for weight loss drug MariTide
MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...
Fierce Biotech4d
Amgen enters Maritime, launching 2 late-stage obesity trials for MariTide
Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly ...
STAT3d
Amgen starts late-stage studies of MariTide
Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese ...
BioPharma Dive3d
Amgen readies pivotal MariTide trials; Novo offers discounted Wegovy
Phase 3 studies for Amgen’s closely watched obesity drug were posted on a federal database. Elsewhere, the FDA cleared for ...
Amgen begins late-stage trials for obesity therapy
Amgen (NASDAQ:AMGN) stock in focus as company starts Phase 3 trials for obesity drug MariTide, aiming to challenge Eli Lilly ...
2 Dividend Stocks to Buy for a Lifetime of Passive Income
Dividend investors don't buy shares of companies hoping they will suspend their payouts soon. The longer a corporation ...
This Could Be the Best GLP-1 Stock to Buy in 2025
That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...
NBC DFW4d
Amgen starts two critical late-stage trials for weight loss drug MariTide
Amgen said it has started two critical late-stage trials for its experimental weight loss injection, MariTide, another step in its bid to enter the booming obesity drug market. MariTide is a ...